Charles River Laboratories International Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Charles River Laboratories International stock.
View analyst ratings for Charles River Laboratories International or view top-rated stocks.

Wall Street analysts have given Charles River Laboratories International a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Charles River Laboratories International wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Charles River Laboratories International saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 819,800 shares, an increase of 29.6% from the May 13th total of 632,500 shares. Based on an average trading volume of 597,300 shares, the short-interest ratio is presently 1.4 days. Currently, 1.7% of the shares of the stock are short sold.
View Charles River Laboratories International's Short Interest.

Charles River Laboratories International is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Charles River Laboratories International.

Charles River Laboratories International, Inc. (NYSE:CRL) posted its quarterly earnings results on Monday, May, 3rd. The medical research company reported $2.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.34. The medical research company had revenue of $824.60 million for the quarter, compared to analysts' expectations of $798.52 million. Charles River Laboratories International had a trailing twelve-month return on equity of 22.54% and a net margin of 12.33%. Charles River Laboratories International's revenue was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.84 EPS.
View Charles River Laboratories International's earnings history.

Charles River Laboratories International's stock was trading at $136.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRL stock has increased by 158.9% and is now trading at $353.70.
View which stocks have been most impacted by COVID-19.

Charles River Laboratories International updated its FY 2021 earnings guidance on Tuesday, May, 18th. The company provided earnings per share (EPS) guidance of 9.750-10.000 for the period, compared to the Thomson Reuters consensus estimate of $9.240. The company issued revenue guidance of $3.48 billion-$3.54 billion, compared to the consensus revenue estimate of $3.38 billion.

14 analysts have issued 12 month price objectives for Charles River Laboratories International's shares. Their forecasts range from $192.00 to $400.00. On average, they expect Charles River Laboratories International's share price to reach $325.43 in the next year. This suggests that the stock has a possible downside of 8.0%.
View analysts' price targets for Charles River Laboratories International or view top-rated stocks among Wall Street analysts.

291 employees have rated Charles River Laboratories International CEO James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among Charles River Laboratories International's employees.

Some companies that are related to Charles River Laboratories International include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Bio-Techne (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of CRL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), The Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), salesforce.com (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Charles River Laboratories International's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.13%), Massachusetts Financial Services Co. MA (2.74%), Kayne Anderson Rudnick Investment Management LLC (2.51%), William Blair Investment Management LLC (1.97%), Ameriprise Financial Inc. (1.81%) and Brown Advisory Inc. (1.75%). Company insiders that own Charles River Laboratories International stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Robert J Bertolini, Stephen D Chubb and William D Barbo.
View institutional ownership trends for Charles River Laboratories International.

CRL stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, Renaissance Technologies LLC, Ameriprise Financial Inc., TimesSquare Capital Management LLC, Neuberger Berman Group LLC, Sculptor Capital LP, AQR Capital Management LLC, and Acadian Asset Management LLC. Company insiders that have sold Charles River Laboratories International company stock in the last year include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Stephen D Chubb, and William D Barbo.
View insider buying and selling activity for Charles River Laboratories International or view top insider-selling stocks.

CRL stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Viking Global Investors LP, BlackRock Inc., Kayne Anderson Rudnick Investment Management LLC, Redmile Group LLC, Riverbridge Partners LLC, Point72 Asset Management L.P., and JPMorgan Chase & Co..
View insider buying and selling activity for Charles River Laboratories International or or view top insider-buying stocks.

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRL stock can currently be purchased for approximately $353.70.

Charles River Laboratories International has a market capitalization of $17.77 billion and generates $2.92 billion in revenue each year. The medical research company earns $364.30 million in net income (profit) each year or $8.13 on an earnings per share basis.

Charles River Laboratories International employs 18,400 workers across the globe.

The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Cognate BioServices, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, Retrogenix Limited, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, Tektagen Inc, WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..

Charles River Laboratories International was founded in 1947.

The official website for Charles River Laboratories International is www.criver.com.

Charles River Laboratories International is headquartered at 251 BALLARDVALE STREET, WILMINGTON MA, 01887.

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]